MedTrace Logo

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

NCT00517920 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-01-04

No results posted yet for this study

Summary

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Conditions

Interventions

DRUG

ABT-869

0.25 mg/kg QD

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Justin Ricker, MD · AbbVie

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-06-30
Completion
2012-06-30

Countries

  • United States
  • Canada
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517920 on ClinicalTrials.gov